McDermott Advises the Shareholders of LimFlow on its Sale to Inari Medical, Inc for an Upfront Amount of USD 250 Million
Inari Medical, Inc. (NASDAQ: NARI) (Inari), a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, has announced that it has entered into a definitive agreement to acquire LimFlow, S.A., a privately held pioneer in limb salvage for patients with chronic limb-threatening ischemia (CLTI). Under the terms of the agreement, Inari will pay USD 250 million in cash at closing and LimFlow will be eligible to receive additional cash payments based on certain commercial and reimbursement milestones.
The transaction closed on November 15, 2023.
McDermott Will & Emery led by Bertrand Delafaye and Smith Alpert advised the shareholders of Limflow SA with a French team comprised of Natacha Vasak, Alexandre Bomet and Alice Villagrasa on the corporate side and Romain Desmonts and Fanny Le Pogam on the tax aspects. The US team led by Smith Alpert was made up of several US teams in Tax, IP and Employment Benefits. The McDermott team also worked on the French and US regulatory aspects, with Sabine Naugès and Benoit Feroldi in Paris.
McDermott Will & Emery partners with leaders around the world to fuel missions, knock down barriers and shape markets. Our team works seamlessly across practices and industries to deliver highly effective solutions that propel success. More than 1,400 lawyers strong, we bring our personal passion and legal prowess to bear in every matter for our clients and the people they serve.